<div id="readability-page-1" class="page"><p>UBS Group AG reduced its stake in shares of  Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 42.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 126,674 shares of the company's stock after selling 93,687 shares during the quarter. UBS Group AG owned 0.47% of Eton Pharmaceuticals worth $2,142,000 as of its most recent filing with the Securities and Exchange Commission.</p><div><p><span></span><span>Get <strong>Eton Pharmaceuticals</strong> alerts:</span></p></div><p>Several other institutional investors and hedge funds also recently added to or reduced their stakes in ETON. Millennium Management LLC grew its position in  Eton Pharmaceuticals by 156.3% during the first quarter. Millennium Management LLC now owns 355,929 shares of the company's stock worth $4,620,000 after buying an additional 217,042 shares during the period.  Goldman Sachs Group Inc. grew its position in  Eton Pharmaceuticals by 34.9% during the first quarter. Goldman Sachs Group Inc. now owns 175,220 shares of the company's stock worth $2,274,000 after buying an additional 45,341 shares during the period.  Jane Street Group LLC grew its position in  Eton Pharmaceuticals by 49.1% during the first quarter. Jane Street Group LLC now owns 95,919 shares of the company's stock worth $1,245,000 after buying an additional 31,596 shares during the period.  JPMorgan Chase &amp; Co. grew its position in  Eton Pharmaceuticals by 114.5% during the second quarter. JPMorgan Chase &amp; Co. now owns 242,580 shares of the company's stock worth $3,457,000 after buying an additional 129,467 shares during the period.  Finally, Legal &amp; General Group Plc acquired a new position in  Eton Pharmaceuticals during the second quarter worth about $41,000. 27.86% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Insider Activity</h2><p>In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of the company's stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the sale, the insider owned 25,249 shares of the company's stock, valued at $794,586.03. This represents a 43.80% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 100,000 shares of company stock valued at $3,229,921 over the last quarter. 16.49% of the stock is owned by corporate insiders. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several research analysts have weighed in on ETON shares. Craig Hallum upped their target price on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. B. Riley Financial upped their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 20th. HC Wainwright upped their target price on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, May 15th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Saturday, March 21st. Finally, Zacks Research downgraded shares of Eton Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Friday, April 17th. Three investment analysts have rated the stock with a Buy rating, one  has given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, Eton Pharmaceuticals presently has a consensus rating of &#34;Hold&#34; and an average target price of $41.00.</p><p><b>Read Our Latest Report on ETON</b></p><h2>Eton Pharmaceuticals Stock Up 3.5%</h2><p>Shares of NASDAQ ETON opened at $32.40 on Thursday. Eton Pharmaceuticals, Inc. has a 12-month low of $13.09 and a 12-month high of $35.66. The company has a market capitalization of $887.44 million, a PE ratio of -462.79 and a beta of 0.82. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The firm's 50-day moving average is $26.59 and its two-hundred day moving average is $20.03. </p><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million during the quarter, compared to analysts' expectations of $22.31 million.  Equities analysts anticipate that  Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year. </p><h2>Eton Pharmaceuticals Company Profile</h2> (Free Report)<p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.  </p><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p><h2>Read More</h2><ul><li>Five stocks we like better than Eton Pharmaceuticals</li><li>Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak</li><li>TeraWulf Bets on Power Infrastructure to Lead AI Build-Out</li><li>Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case</li><li>Keysight: The AI and Defense Stock Seeing Big Price Target Boosts</li></ul><p><strong>Want to see what other hedge funds are holding ETON?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ETON

LABU

ARKG

<p>UBS Group AG reduced its stake in Eton Pharmaceuticals, Inc. by 42.5% in Q4, owning 126,674 shares worth $2.14 million. Other institutional investors, including Millennium Management and Goldman Sachs, increased their stakes. Insider David Krempa sold 19,679 shares, reducing his ownership by 43.80%. Analysts have mixed ratings on ETON, with a consensus rating of 'Hold' and an average target price of $41.00. Eton's shares opened at $32.40, with a market cap of $887.44 million.</p>

Market Beat

Eton Pharmaceuticals

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares US Pharma

SPDR S&P Biotech

UBS Group AG

Goldman Sachs

JPMorgan Chase

Legal & General Group Plc

GS Hldg R

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG